{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:07:38Z","timestamp":1648663658024},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T00:00:00Z","timestamp":1366848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00520-013-1820-9","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T13:03:15Z","timestamp":1367413395000},"page":"2085-2086","source":"Crossref","is-referenced-by-count":1,"title":["Emerging new therapeutic alternatives for the management of cancer cachexia: recent insights"],"prefix":"10.1007","volume":"21","author":[{"given":"Shailendra","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"issue":"1","key":"1820_CR1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","volume":"21","author":"JM Garcia","year":"2013","unstructured":"Garcia JM, Friend J, Allen S (2013) Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21(1):129\u2013137. doi: 10.1007\/s00520-012-1500-1","journal-title":"Support Care Cancer"},{"key":"1820_CR2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-011-0039-1","volume":"2","author":"R Dallmann","year":"2011","unstructured":"Dallmann R, Weyermann P, Anklin C et al (2011) The orally active melanocortin-4 receptor antagonist BL-6020\/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2:163\u2013174","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1820_CR3","first-page":"7","volume":"3","author":"Y Elkina","year":"2012","unstructured":"Elkina Y, Braun T, Brines M, Cerami A, Anker SD, Springer J (2012) Tissue-protective effect of the non-hematopoetic erythropoetin analogues ARA284 and ARA286 in the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 3:7\u201320","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1820_CR4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1743-7075-9-76","volume":"9","author":"M Olivan","year":"2012","unstructured":"Olivan M, Springer J, Busquets S et al (2012) Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutr Metab (Lond) 9:76, 7075-9-76","journal-title":"Nutr Metab (Lond)"},{"key":"1820_CR5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13539-011-0046-2","volume":"2","author":"AJ Stewart Coats","year":"2011","unstructured":"Stewart Coats AJ, Srinivasan V, Surendran J et al (2011) The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic\/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2:201\u2013207","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1820_CR6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/cbt.12.11.18134","volume":"12","author":"ML Asp","year":"2011","unstructured":"Asp ML, Tian M, Kliewer KL, Belury MA (2011) Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther 12:957\u2013965","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"1820_CR7","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","volume":"31","author":"K Ando","year":"2013","unstructured":"Ando K, Takahashi F, Motojima S et al (2013) Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 31(6):e69\u2013e72","journal-title":"J Clin Oncol"},{"key":"1820_CR8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.cmet.2011.03.020","volume":"13","author":"SD Kunkel","year":"2011","unstructured":"Kunkel SD, Suneja M, Ebert SM et al (2011) mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 13:627\u2013638","journal-title":"Cell Metab"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1820-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1820-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:04:26Z","timestamp":1559095466000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1820-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}